Intervention
Treatment of osteoporosis or osteopenia
Offer treatment for osteoporosis or osteopenia using lifestyle interventions with or without medication in line with published clinical guidance on management of osteoporosis/osteopenia.
Medication for osteoporosis/osteopenia:
Management plans are highly individualized and recommendations may differ according to sex, investigation findings, personalized fracture risk assessment results, and whether or not glucocorticoid use is a contributing factor to bone mineral density loss.
It is recommended that treatment is stratified according to fracture risk; combination or sequential treatment with different classes of medication may be required to lower risk to acceptable levels in people at particularly high risk of future fracture.
Patient adherence to prescribed treatment is key. An estimated 25% to 30% of people with osteoporosis do not start taking their prescribed medication and 50% or more do not continue treatment after 1 year; nonadherence to treatment is associated with higher morbidity and mortality.
Ensure a good foundation for treatment is in place, including focused support and monitoring early in treatment, which may help improve a patient’s long-term adherence to prescribed treatment and, consequently, fracture outcomes.
Ask questions about patient preferences and address fears and misconceptions as part of the medication selection process, as this can not only promote better adherence to prescribed treatment but also lead to better outcomes in terms of prevention of fractures and disability.
Lifestyle interventions for osteoporosis:
A multicomponent program is recommended, encompassing:
Progressive resistance training
Balance training
Back extensor strengthening
Core stabilizers
Cardiovascular conditioning
Impact or ground-reaction forces to stimulate bone
Note that recreational pursuits and athletic activities that exert intense forces on weakened bone and/or involve abrupt or high-impact loading can break bones in people with osteoporosis.
For safety, it is recommended that any program of physical activity is developed and supervised by certified fitness personnel experienced with skeletal fragility in older adults.
See Osteoporosis.
Goal
Increased bone mineral density; improved falls outcomes; reduced fracture risk
Like any lifelong chronic disease, osteoporosis is most successfully managed with continued therapy and monitoring.
Recommended duration of treatment varies according to patient characteristics and the type of medication used.
Periodically review pharmacotherapy to determine whether treatment should be continued, changed, stopped, or resumed. It is reasonable to evaluate patients every 1 to 2 years during any hiatus from active bisphosphonate treatment.
For patients on pharmacological therapy, a reasonable 3-year target outcome could be to increase the T-score from −2.8 to > −2.5 and have no fractures.
Stable bone mineral density and a year with no new fractures could be a measurable goal for someone with low bone mineral density and prior fragility fractures.
If the patient is not on track to reach their target or does not reach their target, consider clinical reassessment and possibly a change in therapy.